Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

We evaluated long-term outcomes of 60 patients with chronic lymphocytic leukemia treated with an initial therapy of lenalidomide. At a median follow-up of 4 years, time-to-treatment failure has not been reached and overall survival is 82%. Thirty-five (58%) patients had a response lasting >36 mon...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Strati, Paolo, Keating, Michael J., Wierda, William G., Badoux, Xavier C., Calin, Steliana, Reuben, James M., O’Brien, Susan, Kornblau, Steven M., Kantarjian, Hagop M., Gao, Hui, Ferrajoli, Alessandra
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2013
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123325/
https://ncbi.nlm.nih.gov/pubmed/23801633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-04-495341
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky